HK1049442B - Male contraceptive formulation comprising norethisterone and testosterone undecanoate - Google Patents

Male contraceptive formulation comprising norethisterone and testosterone undecanoate Download PDF

Info

Publication number
HK1049442B
HK1049442B HK03101578.5A HK03101578A HK1049442B HK 1049442 B HK1049442 B HK 1049442B HK 03101578 A HK03101578 A HK 03101578A HK 1049442 B HK1049442 B HK 1049442B
Authority
HK
Hong Kong
Prior art keywords
norethisterone
administration
derivative
net
testosterone
Prior art date
Application number
HK03101578.5A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1049442A1 (en
Inventor
Eberhard Nieschlag
Axel Kamischke
Michael Oettel
Alexander Ruebig
Ekkerhard Schillinger
Ursula-Friederike Habenicht
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HK1049442A1 publication Critical patent/HK1049442A1/en
Publication of HK1049442B publication Critical patent/HK1049442B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK03101578.5A 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone and testosterone undecanoate HK1049442B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50372900A 2000-02-15 2000-02-15
EP20000200493 2000-02-15
EP00200493 2000-02-15
US20000503729 2000-02-15
PCT/IB2001/000188 WO2001060376A1 (en) 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone

Publications (2)

Publication Number Publication Date
HK1049442A1 HK1049442A1 (en) 2003-05-16
HK1049442B true HK1049442B (en) 2007-06-15

Family

ID=26071832

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101578.5A HK1049442B (en) 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone and testosterone undecanoate

Country Status (26)

Country Link
EP (2) EP1267885B8 (enExample)
JP (1) JP2003522795A (enExample)
KR (1) KR20020086905A (enExample)
CN (1) CN1423560A (enExample)
AT (2) ATE474580T1 (enExample)
AU (1) AU2001230447A1 (enExample)
BG (1) BG107066A (enExample)
BR (1) BR0108411A (enExample)
CA (1) CA2398063A1 (enExample)
CY (1) CY1106639T1 (enExample)
CZ (1) CZ20022691A3 (enExample)
DE (2) DE60142647D1 (enExample)
DK (1) DK1267885T3 (enExample)
EE (1) EE200200454A (enExample)
ES (1) ES2282230T3 (enExample)
HK (1) HK1049442B (enExample)
HU (1) HUP0300128A3 (enExample)
IL (1) IL151219A0 (enExample)
MX (1) MXPA02007675A (enExample)
NO (1) NO20023607L (enExample)
PL (1) PL357185A1 (enExample)
PT (1) PT1267885E (enExample)
RU (1) RU2002124602A (enExample)
SI (1) SI1267885T1 (enExample)
SK (1) SK11602002A3 (enExample)
WO (1) WO2001060376A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
JP4417838B2 (ja) 2002-07-24 2010-02-17 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ７α−置換された１１α−ヒドロキシステロイドの微生物的生成方法
BR0312922A (pt) * 2002-07-25 2005-07-12 Schering Ag Composição contendo um androgênio 11 beta halogênio-esteróide e um gestagênio assim como um contraceptivo masculino à base dessa composição
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN101352443B (zh) * 2007-07-23 2011-01-12 中国科学院动物研究所 哺乳动物雄性不育剂
CN112074269A (zh) 2018-03-23 2020-12-11 美卓实验室 用于男性避孕的非激素组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714420A1 (de) * 1976-06-01 1977-12-08 Int Pregnancy Advisory Service Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
DE19650352A1 (de) * 1996-12-04 1998-07-30 Jenapharm Gmbh Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann

Also Published As

Publication number Publication date
HUP0300128A2 (en) 2003-05-28
DE60127103T2 (de) 2007-11-22
DK1267885T3 (da) 2007-07-09
RU2002124602A (ru) 2004-03-10
NO20023607D0 (no) 2002-07-30
EE200200454A (et) 2003-12-15
BR0108411A (pt) 2003-03-11
ATE355844T1 (de) 2007-03-15
SK11602002A3 (sk) 2003-03-04
CA2398063A1 (en) 2001-08-23
DE60127103D1 (de) 2007-04-19
HK1049442A1 (en) 2003-05-16
ATE474580T1 (de) 2010-08-15
EP1666044B1 (en) 2010-07-21
KR20020086905A (ko) 2002-11-20
PL357185A1 (en) 2004-07-26
CY1106639T1 (el) 2012-01-25
AU2001230447A1 (en) 2001-08-27
HUP0300128A3 (en) 2004-03-29
EP1267885B8 (en) 2007-06-20
WO2001060376A1 (en) 2001-08-23
SI1267885T1 (sl) 2007-08-31
ES2282230T3 (es) 2007-10-16
CN1423560A (zh) 2003-06-11
NO20023607L (no) 2002-10-15
EP1267885B1 (en) 2007-03-07
EP1267885A1 (en) 2003-01-02
JP2003522795A (ja) 2003-07-29
EP1666044A1 (en) 2006-06-07
CZ20022691A3 (cs) 2003-01-15
IL151219A0 (en) 2003-04-10
DE60142647D1 (de) 2010-09-02
PT1267885E (pt) 2007-05-31
MXPA02007675A (es) 2004-02-26
BG107066A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
US20060142257A1 (en) Male contraceptive formulation comprising norethisterone
US7025979B2 (en) Male contraceptive formulation comprising norethisterone
EP0811381B1 (en) A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
Swerdloff et al. Control of LH and FSH secretion in the male: evidence that aromatization of androgens to estradiol is not required for inhibition of gonadotropin secretion
DE60209907T2 (de) Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen
EP2861233B1 (en) Transdermal hormone replacement therapies
EP1482925B1 (en) 5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropl]-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
US20040092494A9 (en) Method of increasing testosterone and related steroid concentrations in women
JPH04504848A (ja) エストロゲン感受性疾患の治療のための組合せ療法
EP1267885B1 (en) Male contraceptive formulation comprising norethisterone and testosterone undecanoate
TW200528073A (en) Transdermal delivery of hormones without the need of penetration enhancers
EP0479867B1 (en) Compositions useful as contraceptives in males
HK1090576A (en) Male contraceptive formulation comprising norethisterone
GB1569286A (en) Oily depot solutions of gestagents for intramuscular injection
CN101332174A (zh) 二氢睾酮外用制剂及其药物用途
US7169769B2 (en) 17α-hydroxy-14β-steroids with hormonal effect
PL214858B1 (pl) Środek leczniczy na bazie noretysteronu lub jego farmaceutycznie dopuszczalnej pochodnej i estradiolu lub jego farmaceutycznie dopuszczalnej pochodnej

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130215